Objective:To compare the polio antibody level of healthy children in Jiangsu Province before and after the conversion of (inactivated poliovirus vaccine, IPV) immunization program.Methods:200 serum samples of healthy children under 5 years old in Jiangsu Province were collected before and after the vaccine conversion, and the neutralizing antibody against poliomyelitis was measured using the micro cell neutralization test. We compared the differences in the positive rate and geometric mean titer (GMT) of polio antibody before and after vaccine conversion.Results:Before vaccine conversion, positive rates of antibody against poliovirus type Ⅰ and Ⅲ were 98.50% and 92.00%, with GMTs of 1∶100.43 and 1∶23.34, respectively. After the conversion, positive rates of polio antibody type I and Ⅲ were 99.00% and 96.00%, GMT were 1∶213.04 and 1∶121.10.Conclusions:There is a difference in immunization effect before and after the polio vaccine conversion, and the antibody level of the population after vaccine conversion is higher than that before vaccine conversion. It is recommended to gradually increase the IPV dose in order to finally achieve the whole course of IPV inoculation.

Objective:To analyze immune effects of children with different immunization schedules after the conversion of polio vaccine immunization strategy.Methods:Serum samples of children with different immunization schedules were collected in 2018 and 2021 respectively. The neutralizing antibody against poliovirus was detected by micro cell neutralization test, and the antibody positive rate and geometric mean titer (GMT) were analyzed.Results:The positive rates of neutralizing antibodies against type I and type III poliovirus in children immunized with two doses inactivated polio vaccine (IPV) and two doses bivalent live attenuated oral polio vaccine (bOPV), one dose IPV and 3 doses bOPV were both 100.00%. The GMT for type I poliovirus antibody were higher than 1∶300, and for type III poliovirus antibody were close to 1∶200. In children vaccinated with IPV, the positive rates of type I and III poliovirus antibodies were 96.72% and 95.08%, and the GMT for type I and III poliovirus antibodies were 1∶96.72 and 1∶48.72, respectively. In children vaccinated with trivalent live attenuated oral polio vaccine (tOPV) only, the positive rates of type I and III poliovirus antibodies were 98.68% and 96.05%, and the GMT for type I and III poliovirus antibodies were 1∶126.84 and 1∶68.22, respectively. In children vaccinated with three doses tOPV and one dose bOPV, the positive rates of type I and III poliovirus antibodies were 100.00% and 98.57%, and the GMT for type I and III poliovirus antibodies were 1∶214.21 and 1∶94.17, respectively.Conclusions:Children who received sequential immunization with IPV and live attenuated oral polio vaccine (OPV) have a high level of positive rate and GMT of neutralizing antibody against poliovirus type I and III.

OBJECTIVETo analyze the five-year effectiveness of the people living with HIV/AIDS who initially received highly active antiretroviral therapy (HAART) in Jiangsu province.

METHODSHIV/AIDS initially received HAART from 1 Jan 2005 to 31 May 2014 in Jiangsu province with the CD4(+)T cell count tested in baseline, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years after treatment initiation were selected. According to their retrospectively collected baseline and follow-up data, statistical analysis was performed using SPSS 16.0 software to analyze the variation of CD4(+)T counts and its impact factors in different times after treatment initiation.

RESULTSA total of 200 patients were included. A total of 134 patients were men, and 66 were women, the ratio of male to female was 2.03: 1; mean age was (39.7 ± 10.3) years old; 69.0% (138/200) of the patients married; 53.0% (106/200) as the most were infected with HIV through heterosexual transmission, and followed by men who have sex with men (MSM) (25.5%, 51/200); taken together as 78.5% (157/200).58.5% (117/200) were treated in the CDC. The mean (95%CI) baseline CD4(+)T cell count of cases was 106.9 (93.3-120.5) cells/µl; the CD4(+)T count tested in 6 months, 1 year, 2 years, 3 years, 4 years and 5 years after treatment initiation were 107.3, 152.9, 221.6, 260.0, 281.3 and 316.4 cells/µl more than baseline respectively; the CD4(+)T count after treatment initiation has increased over time (F = 201.06, P < 0.01) . The mean(95%CI) CD4(+)T count tested in 5 years after treatment initiation can increase to 540.7(445.4-635.9) cells/µl with a baseline CD4(+)T count more than 200 cells/µl, but in the subgroups with a baseline CD4(+)T count less than or equal to 50 cells/µl, 51-100 cells/µl, 101-150 cells/µl and 151-200 cells/µl, it only can reach to 431.4 (375.9-487.0), 400.0 (339.9-460.2), 380.3 (330.6-430.0) and 412.1 (369.3-454.8) cells/µl respectively. The mean (95%CI) CD4(+)T count tested in 5 years after treatment initiation with 1 baseline symptom categories can increase to 449.2 (392.2-506.2) cells/µl, while 409.1(317.8-500.5)cells/µl in the subgroup with baseline symptom categories more than or equal to 2. The CD4(+)T after treatment increased slowly associated with a lower baseline CD4(+)T count level and more baseline symptom categories (F values were 3.96 and 2.35, P < 0.01).

CONCLUSIONIt has a remarkable effectiveness for HIV/AIDS treatment in Jiangsu province. The patients with a baseline CD4(+)T count more than 200 counts/µl have a better immune function recovery.

Acquired Immunodeficiency Syndrome ; Antiretroviral Therapy, Highly Active ; CD4 Lymphocyte Count ; Female ; Follow-Up Studies ; HIV Infections ; Humans ; Male

Objective: To investigate the immunity to mumps after administrating measles-mumps-rubella vaccine (MMR) among children aged 2-7 years old in Jiangsu province in 2015. Methods: A total of 4 190 healthy children aged 2-7 years old, living in local places for at least 3 months, and having been vaccinated at least 1 dose MMR were recruited to the study from Wujin district of Changzhou city, Gaogang district of Taizhou city and Ganyu district of Lianyungang city by using stratified cluster random sampling method between September and November, 2015. Those who did not accept MMR vaccination, who refused venous blood collection, who had affected mumps according to the memory of parents or teachers and who were diagnosed serious disease by clinical doctors were excluded from study. The self-designed questionnaire was used to collect the general information of the subjects and their MMR immunization history; and 0.5-2.0 ml of venous blood was collected from each subject. ELISA was used to detect the mumps antibody level in the serum of patients. Positive was defined as the antibody level ≥108 mU/ml, and negative as <108 mU/ml. χ² test was used to compare the difference in positive rates among subjects; and analysis of variance was used to compare the GMC changes in different time points after MMR vaccination. Results: Among 4 190 children, 2 280 were males (54.42%) and 1 910 were females(45.58%), and the positive rate of IgG antibody was 81.38% (3 344). There were 3 156 (95.18%) children vaccinated with one dose MMR, 187 (4.80%) children with two dose MMR, and 1 (0.02%) child with three dose MMR. The difference in positive rate of IgG antibody among different aged subjects showed statistical significance (χ²=58.61, P<0.001), the highest positive rate was in group of subjects aged 4-5 years old, at 89.43% (406/454), while the lowest positive rate was found among subjects aged 6-7 years old, at 75.63% (1 648/2 179). The positive rate after one dose of MMR vaccination was 79.14% (3 156/3 988), significantly less than it after two doses (93.03%, 187/201) (χ²=22.93, P<0.001). The GMC level at years<1, 1-<2, 2-<3, 3-<4, ≥4 following one dose MMR in the 3 988 children was 152.47, 227.78, 167.08, 126.91, 79.43 mU/ml, whose difference was statistically significant (F=51.29, P<0.001). Conclusion The sero-prevalence of IgG antibody in the children aged 2-7 years old in Jiangsu province was high. The positive rate among who received two doses MMR was significantly higher than it among who received just one dose, and the GMC level waned with times.

Objective To analyze the five-year effectiveness of the people living with HIV/AIDS who initially received highly active antiretroviral therapy ( HAART ) in Jiangsu province.Methods HIV/AIDS initially received HAART from 1 Jan 2005 to 31 May 2014 in Jiangsu province with the CD 4 +T cell count tested in baseline ,6 months,1 year,2 years,3 years,4 years and 5 years after treatment initiation were selected.According to their retrospectively collected baseline and follow-up data, statistical analysis was performed using SPSS 16.0 software to analyze the variation of CD 4 +T counts and its impact factors in different times after treatment initiation.Results A total of 200 patients were included.A total of 134 patients were men ,and 66 were women , the ratio of male to female was 2.03∶1; mean age was ( 39.7 ± 10.3) years old;69.0%(138/200) of the patients married;53.0%(106/200) as the most were infected with HIV through heterosexual transmission,and followed by men who have sex with men(MSM) (25.5%, 51/200);taken together as 78.5%( 157/200 ).58.5%( 117/200 ) were treated in the CDC .The mean (95%CI) baseline CD4 +T cell count of cases was 106.9(93.3-120.5) cells/μl;the CD4 +T count tested in 6 months,1 year,2 years,3 years,4 years and 5 years after treatment initiation were 107.3,152.9,221.6, 260.0,281.3 and 316.4 cells/μl more than baseline respectively;the CD4 +T count after treatment initiation has increased over time(F=201.06,P<0.01).The mean(95%CI) CD4 +T count tested in 5 years after treatment initiation can increase to 540.7(445.4-635.9) cells/μl with a baseline CD4 +T count more than 200 cells/μl, but in the subgroups with a baseline CD 4+T count less than or equal to 50 cells/μl, 51-100 cells/μl, 101-150 cells/μl and 151-200 cells/μl,it only can reach to 431.4(375.9-487.0),400.0 (339.9-460.2),380.3(330.6-430.0)and 412.1(369.3-454.8) cells/μl respectively.The mean (95%CI) CD4 +T count tested in 5 years after treatment initiation with 1 baseline symptom categories can increase to 449.2(392.2-506.2)cells/μl, while 409.1 ( 317.8-500.5 ) cells/μl in the subgroup with baseline symptom categories more than or equal to 2.The CD4+T after treatment increased slowly associated with a lower baseline CD4 +T count level and more baseline symptom categories (F values were 3.96 and 2.35,P<0.01).Conclusion It has a remarkable effectiveness for HIV/AIDS treatment in Jiangsu province.The patients with a baseline CD 4 +T count more than 200 counts/μl have a better immune function recovery.

Objective To analyze the five-year effectiveness of the people living with HIV/AIDS who initially received highly active antiretroviral therapy ( HAART ) in Jiangsu province.Methods HIV/AIDS initially received HAART from 1 Jan 2005 to 31 May 2014 in Jiangsu province with the CD 4 +T cell count tested in baseline ,6 months,1 year,2 years,3 years,4 years and 5 years after treatment initiation were selected.According to their retrospectively collected baseline and follow-up data, statistical analysis was performed using SPSS 16.0 software to analyze the variation of CD 4 +T counts and its impact factors in different times after treatment initiation.Results A total of 200 patients were included.A total of 134 patients were men ,and 66 were women , the ratio of male to female was 2.03∶1; mean age was ( 39.7 ± 10.3) years old;69.0%(138/200) of the patients married;53.0%(106/200) as the most were infected with HIV through heterosexual transmission,and followed by men who have sex with men(MSM) (25.5%, 51/200);taken together as 78.5%( 157/200 ).58.5%( 117/200 ) were treated in the CDC .The mean (95%CI) baseline CD4 +T cell count of cases was 106.9(93.3-120.5) cells/μl;the CD4 +T count tested in 6 months,1 year,2 years,3 years,4 years and 5 years after treatment initiation were 107.3,152.9,221.6, 260.0,281.3 and 316.4 cells/μl more than baseline respectively;the CD4 +T count after treatment initiation has increased over time(F=201.06,P<0.01).The mean(95%CI) CD4 +T count tested in 5 years after treatment initiation can increase to 540.7(445.4-635.9) cells/μl with a baseline CD4 +T count more than 200 cells/μl, but in the subgroups with a baseline CD 4+T count less than or equal to 50 cells/μl, 51-100 cells/μl, 101-150 cells/μl and 151-200 cells/μl,it only can reach to 431.4(375.9-487.0),400.0 (339.9-460.2),380.3(330.6-430.0)and 412.1(369.3-454.8) cells/μl respectively.The mean (95%CI) CD4 +T count tested in 5 years after treatment initiation with 1 baseline symptom categories can increase to 449.2(392.2-506.2)cells/μl, while 409.1 ( 317.8-500.5 ) cells/μl in the subgroup with baseline symptom categories more than or equal to 2.The CD4+T after treatment increased slowly associated with a lower baseline CD4 +T count level and more baseline symptom categories (F values were 3.96 and 2.35,P<0.01).Conclusion It has a remarkable effectiveness for HIV/AIDS treatment in Jiangsu province.The patients with a baseline CD 4 +T count more than 200 counts/μl have a better immune function recovery.

Objective:To evaluate the detection ability of two kinds of high-throughput method to determine neutralizing antibodies based on a microneutralization test (MNT).Methods:Serum samples were collected from the early phase and follow-up period (117 samples in total) for neutralizing antibody testing. They were tested using MNT, pseudovirus neutralization assay (PBNA), competitive inhibition assay (including enzyme-linked immunosorbent assay (ELISA) and chemiluminescence immunoassay (CLIA)) to evaluate the correlation coefficients and threshold values for the effectiveness of these high-throughput neutralizing antibody assays.Results:The correlation coefficients for PBNA, ELISA, and CLIA relative to MNT were 0.760, 0.778, and 0.725, respectively, for individuals infected with 2019-nCoV. The area under the ROC curve was 0.901 for a cutoff value of 50 for the PBNA assay, 0.934 for a cutoff value of 1∶8 for the ELISA assay and 0.838 for a cutoff value of 1.28AU/ml for the CLIA assay when the threshold value for the microneutralization test was taken as 1: 10 (less than 1: 10 is considered negative).Conclusions:The high-throughput method for the detection of COVID-19 neutralizing antibodies are scientific and feasible, and provide an important technical tool for the regular prevention and control of the epidemic.